Loading…
Sila Realty Trust, Inc.
NYSE: SILA Real Estate IT 🔎 Screen
🏹 Trader: 🎯 Near 52W High 📊 High Volume 💎 VCP Breakout View all →
$1.7B
Market Cap
38.9
P/E
PEG
3.2%
ROCE
0.1%
ROE
0.54
D/E
32.9%
OPM
0.0%
% from 52W High
79
α RS
🔍 SILA is showing a high-conviction setup because it matches 3 of 37 tracked screener presets, Sector RRG has Health Care in the Leading quadrant with the trail still strengthening, and RS Rating is 79. Net: Broad signal stack, not a recommendation. ? Conviction RRG RS Rating
Sources
Conviction 3/37 · Health Care in Leading quadrant · RS Rating 79
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for SILA including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

Sila Realty Trust, Inc. is a net lease real estate investment trust with a strategic focus on investing in the growing and resilient healthcare sector.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →
📊 MIXED Sila Realty Trust owns $2B+ healthcare REIT with 5.9x EBITDARM coverage
Revenue & Profitability
For the full year 2025, cash NOI was $169.9 million, up 0.8% from $168.6 million in 2024. Same-store cash NOI grew 0.9%. FFO per share increased 3.6% to $2.16, while AFFO per share decreased 5.8% to $2.18. Net debt to EBITDAre was 3.9x, below the target range of 4.5x-5.5x. Total liquidity exceeded $480 million at year-end. Excluding one-time termination fees, cash NOI growth would have been 4.4%.
Outlook
Management highlights the 'silver tsunami' demographic shift, with the entire baby boomer generation reaching 65 or older by 2030, expected to drive total outpatient healthcare spending to nearly $2 trillion. This non-discretionary demand should increase patient volumes and case acuity, supporting stronger operator revenues and more durable income for Sila. The company sees healthcare real estate as vital social infrastructure with limited cyclicality.
Growth Drivers
Key growth levers include selective acquisitions of modern, well-utilized facilities (e.g., $150 million in 2025, $43.1 million in 2026) and redevelopment investments in existing properties at attractive yields. Tenant credit quality is improving as investment-grade sponsors (e.g., Washington Regional Medical Center, Cencora/OneOncology) replace weaker tenants. Planned dispositions of three properties (Henderson, Las Vegas Two, Saginaw) and the Alexandria facility will optimize portfolio quality. Expansion opportunities with existing tenants like PAM Health offer returns 150-200 bps above acquisition cap rates.
Balance Sheet & CapEx
During 2025, Sila completed over $7 million of redevelopment opportunities at compelling risk-adjusted returns. After year-end, it closed on a $43.1 million inpatient rehabilitation facility in Oklahoma City. The company has committed additional capital at its Dover and Overland Park facilities (both leased to PAM Health) and expects further expansion investments in the near future. Redevelopment yields are typically 150-200 basis points higher than going-in capitalization rates on acquisitions. Management also noted a $225-$375 million capacity to deploy to reach target leverage.
Margins
Not explicitly discussed as margin metrics. However, management noted a reduction in G&A and other costs in 2025 due to lower personnel costs and absence of one-time listing fees ($3 million in 2024). Interest expense increased due to new swaps entered into at the end of 2024. AFFO per share declined 5.8% partly due to higher interest expense. The company's strategy focuses on predictable, durable income streams rather than margin expansion.
Key Risks
Key risks include tenant credit exposure, as evidenced by the Alexandria facility vacancy (ASE tenant departure) and the sale of underperforming assets. Interest expense risk from new swaps and maturities. The company's stock is trading at an implied cap rate above 8%, which is higher than acquisition yields, causing management to be cautious on equity issuance. Additionally, the transition of tenants (e.g., Community Health Systems divestitures) and bankruptcy processes (Savannah facility) introduce operational uncertainty.
Generated by AI · Q4 2025 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q4 2025 Q4 2025 2026-02-25
Strong 2025 results included modest NOI growth, improved tenant credit quality, and disciplined capital allocation. Portfolio optimization continued with acquisitions, redevelopments, and selective dispositions, while conservative leverage and ample liquidity position the company for further growth.
Q3 2025 Q3 2025 2025-11-05
Q3 2025 saw strong growth in cash NOI and strategic acquisitions, with robust tenant coverage and a healthy balance sheet. The company remains focused on high-yield healthcare real estate, prudent capital allocation, and expects continued acquisition activity into 2026.
Q2 2025 Q2 2025 2025-08-07
Q2 2025 saw strong operating results, 5% year-over-year cash NOI growth, and robust liquidity. Over $70M in acquisitions are under LOI, share repurchases continued, and the Stoughton asset is being demolished to reduce costs. Portfolio lease rate is now 99.2%.
Q1 2025 Q1 2025 2025-05-08
Solid Q1 2025 results with stable occupancy, strong liquidity, and disciplined acquisitions. AFFO and NOI declined year-over-year due to non-recurring items and tenant bankruptcies, but leverage remains low and the portfolio is well-positioned for long-term growth.
Q4 2024 Q4 2024 2025-02-26
Delivered strong 2024 results with higher net income, robust leasing, and improved tenant credit metrics. Upsized credit facility, maintained low leverage, and targets 7.5%-15% growth in 2025, focusing on accretive acquisitions and disciplined capital allocation.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.